ArticleBMC research notes2026
Association of the FTO rs9939609 variant with glycemic control based on fasting glucose.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of FTO rs9939609 Polymorphism With Obesity and Elevated Glycemic Parameters in a Syrian Population: A Case-Control Study.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes (T2D) affects 11.1% of the global population, underscoring the need for biomarkers that help characterize glycemic control status among treated individuals. We evaluated the association between the FTO variant rs9939609‑A and glycemic control in a Mexican population.
methodsA total of 174 individuals living with T2D from Mérida and Sisal, Yucatán, were included, of whom 85% were receiving oral hypoglycemic agents as main treatment. Glycemic control was defined cross‑sectionally as good (≤ 130 mg/dL, n = 63) or poor (> 130 mg/dL, n = 111) with fasting glucose. Linear mixed models incorporating relevant covariates and a family random intercept were used. Effect size estimates were transformed to logit odds ratios.
resultsAfter adjustment for age, sex, BMI, years since T2D diagnosis, and treatment, the minor allele of rs9939609 (A) was associated with an increased risk of poorer glycemic control, reaching significance under both the additive (OR = 1.145 [1.003-1.307], p = 0.047) and recessive (OR = 1.514 [1.026-2.234], p = 0.038) models. In an alternative model adjusting for waist circumference instead of BMI, the effect of rs9939609‑A in the additive model was slightly attenuated (OR = 1.135 [0.994-1.297], p = 0.063), while the recessive model remained significant (OR = 1.486 [1.010-2.189], p = 0.046).
conclusionsrs9939609-A was associated with poorer glycemic control in this exploratory cohort, but replication in larger and ancestrally characterized samples is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.